Che-Ming Teng

         Professor  Ph.D., National Taiwan University

          Address: Room 43, 11F, College of Medicine, NTU.

          TEL: (02)23123456 --88310

          FAX: (02)23221742

1] Drug discovery on anticancer and antiangiogenesis drugs.

2] Mechanism of thrombosis formation and antithrombotic drugs.

3] Signal transduction in cancer cells (including cell proliferation, apoptosis, differentiation, migration, invasion…etc.)

Our lab mainly focuses on evaluating bioactive compounds extracted from natural products and herbs of traditional Chinese medicine as well as synthetic chemical compounds. We collaborate with many chemical research groups and find out the bioactive compounds which were discovered to have variety functions, such as antiplatelet aggregation, vasodilatation, antithrombosis, antiangiogenesis, and anticancer effects. We hope these research findings will develop the lead compounds and provide the new target of investigation. These bioactive compounds can be used as research tools by their specific action mechanisms. For example, YC-1, a new synthetic compound, inhibits platelets aggregation through activating guanylate cyclase independent of nitric oxide (NO). This indazole analogue is benefit to study the role and function of soluble guanylate cyclase in physiology and pathology. Recently, we found YC-1 also has a multiple-targets antiangiogenesis effect and therefore can be an anticancer agent. Our lab also found several new lead compounds from natural products as anticancer drugs, such as evodiamine, denbinobin, moscatilin, and xanthone. We now collaborate with chemists to develop the derivatives and hope to discover a new therapeutic agent.

Publications:

1] A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expression. Oncotarget 2014 (in press).    [Abstract]

2] A novel class I HDAC inhibitor, MPT0G030, induces cell apotosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin. Oncotarget 5(14):5651-62, 2014.    [Abstract]

3] Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo. Clin Cancer Res 20(5):1274-87, 2014.    [Abstract]

4] Depletion of 4E-BP1 and regulation of autophagy lead to YXM110-induced anti-cancer effects. Carcinogenesis. 34(9):2050-60, 2013.   [Abstract]

5] Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo. PLoS One. 7(8):e43645, 2012.   [Abstract]

Research Interests:

1] Platelet aggregation, adhesion, secretion, and signal transduction.

2] Cell culture: cancer cells, vascular smooth muscle cells, human umbilical vein endothelial cells..

3] Cell proliferation, apoptosis, and differentiation.

4] Animal models: xenografts, tumor metastasis, angiogenesis, thrombus formation, restenosis, sepsis …etc.

1] Aggregometer

2] Luminometer

3] Thermocycler

4] ELISA reader